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broad‑spectrum β‑lactamase 
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and metallo‑carbapenemases
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Bacteria are known to evade β-lactam antibiotic action by producing β‑lactamases (BLs), including 
carbapenemases, which are able to hydrolyze nearly all available β‑lactams. The production of BLs 
represents one of the best known and most targeted mechanisms of resistance in bacteria. We have 
performed the parallel screening of commercially available compounds against a panel of clinically 
relevant BLs: class A CTX‑M‑15 and KPC‑2, subclass B1 NDM‑1 and VIM‑2 MBLs, and the class C P. 
aeruginosa AmpC. The results show that all BLs prefer scaffolds having electron pair donors: KPC‑2 
is preferentially inhibited by sulfonamide and tetrazole‑based derivatives, NDM‑1 by compounds 
bearing a thiol, a thiosemicarbazide or thiosemicarbazone moiety, while VIM‑2 by triazole‑
containing molecules. Few broad‑spectrum BLs inhibitors were identified; among these, compound 
40 potentiates imipenem activity against an NDM‑1‑producing E. coli clinical strain. The binary 
complexes of the two most promising compounds binding NDM‑1 and VIM‑2 were obtained at high 
resolution, providing strong insights to improve molecular docking simulations, especially regarding 
the interaction of MBLs with inhibitors.
β-lactam antibiotics are the most commonly used antimicrobials in the treatment of bacterial infections because 
of their spectrum of activity, clinical effectiveness and safety  profile1. However, the continuous dissemination of 
BLs with an extended spectrum of activity, that is, Extended-Spectrum BLs (ESBLs) and carbapenemases, has 
deeply compromised their efficacy over the years and represents a real menace to public  health2.
Notably, resistance to β-lactam antibiotics in Gram-negative bacteria mostly relies on the production of BLs, 
many of which are plasmid-mediated3. Thus, acquired BLs, due to their association with mobile genetic elements 
commonly encoding other resistance determinants, have led to the emergence of multi-drug resistant (MDR) 
and extensively-drug resistant (XDR)  strains4. Moreover, the evolutionary potential of BLs and their presence 
in the environmental resistome is responsible for the mobilization and acquisition of new genes in response to 
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the introduction of new β-lactams, such as carbapenems, the last resort antibiotics towards which resistance 
rates are dramatically  increasing4–6.
BLs are categorised in two distinct families, according to their catalytic mechanism, and further divided into 
structural classes (Ambler’s  classification7): class A, C, and D serine β-lactamases (SBLs), which utilize a catalytic 
serine for β-lactam hydrolysis, and class B metallo-β-lactamases (MBLs), which, in turn, require divalent zinc 
ions for  catalysis8,9.
Class A includes both plasmid-mediated and chromosomally encoded β-lactamases, such as ESBLs, e.g. 
CTX-M-15, and carbapenemases, e.g. KPC-25,10.
Class C enzymes, mostly chromosomally encoded (e.g. AmpC), are resistant to many suicide BLs inhibitors 
(BLIs), such as clavulanic  acid11, but more efficiently inhibited by recently-approved inhibitors, such as avibactam 
or  taniborbactam12. Some class D members (OXA-24 and -48) can hydrolyse last generation cephalosporins and 
 carbapenems13,14.
Finally, subclass B1 MBLs inactivate nearly all β-lactam antibiotics, with the sole exception of monobactams. 
This class includes variants such as IMP-1, VIM-2 and NDM-1, whose worldwide emergence has characterized 
recent decades. While BLI-containing combinations are commercially available for the treatment of infections 
caused by SBL-producing organisms, none are currently available for MBL-producing isolates, which represent a 
serious threat to human health, due to their commonly broad antibacterial resistance  profile15,16. Such infections, 
indeed, when caused by MBL-producing MDR or XDR strains, often respond only to tigecycline or polymyxins, 
the latter suffering from important tolerability  issues17. The current situation highlights the importance of the 
continuous development of novel BLIs, preferably with broad-spectrum  activity18–20. Unfortunately, the design 
of a BLI blocking SBLs and MBLs is extremely challenging, mainly for the significant differences between BLs, 
in terms of structure and mechanism of hydrolysis (Fig. S1). Currently, only one agent, i.e. taniborbactam, able 
to inhibit both SBLs and MBLs, has reached the stage of clinical development in combination with  cefepime21.
With the aim of identifying novel chemotypes able to inhibit both SBLs and MBLs, we have implemented an 
“in parallel” in silico/in vitro approach to screen a large database of commercially available compounds against 
a panel of clinically relevant enzymes. Computational biology and molecular modelling methods have proven, 
over the years, to be powerful tools in drug design in  general22,23 and in the identification of scaffolds for the 
development of new potential  BLIs24–27. Nevertheless, we must acknowledge that the design of non-covalent 
inhibitors for SBLs, which are known to be targeted by covalent inhibitors mimicking the tetrahedral transition 
state, remains quite  challenging25,28,29. Here, we present the identification of a series of non-covalent scaffolds 
targeting SBLs and concomitantly MBLs, through a large virtual screening study, in vitro validation, microbio-
logical analysis and X-ray crystallography.
Results and discussion
A commercially available library, previously filtered for drug-likeness properties, was screened in silico for 
potential ligands of CTX-M-15 ESBL and KPC-2 carbapenemase, and of NDM-1 and VIM-2 MBLs. The results 
from each screening, i.e. the most interesting molecules for each BL according to the pose in the binding site, 
the number of hydrogen bonds formed with the surrounding residues and the chemical diversity, were carefully 
analysed and guided the final candidate selection. A total of 66 molecules were purchased and subsequently tested 
in enzyme assays to evaluate their potential to inhibit the four above-mentioned enzymes, with the addition of 
AmpC from Pseudomonas aeruginosa, as a representative of class C BLs (structure and inhibition profile of the 
selected compounds are reported in Table 1 and Table S1).
To better appreciate the inhibition profile of the entire library, we classified the compounds in two categories 
having, respectively, inhibition ranging 50–70% or > 70% towards at least one BL (Chart 1). The diagram provides 
a rapid glimpse of the obtained results and of the cross-activity of the compounds towards the different BLs.
The structure of compounds showing at least 70% inhibition, when tested at 200 μM, are shown in Table 2. 
The docking poses of some of them for each targeted BL are shown in Fig. 1.
NDM‑1 inhibition. Twelve molecules were selected in silico as possible MBL NDM-1 inhibitors. Eleven 
of these demonstrated good inhibition potency (≥ 50%), giving a VS success rate of 55% (For VS success rate 
we intend, in this paper, the percentage of compounds having an inhibition percentage ≥ 50% towards a specific 
BL, with respect to those selected as possibly active for that BL). Another twenty molecules, which were selected 
to inhibit SBLs, also performed well (≥ 50%) against NDM-1. Of these thirty-one compounds, 24, 40, 46, 52 
and 54, showed an inhibition activity higher than 70% and were all originally identified as potential ligands of 
a MBL. All the last present a thiol, a thiosemicarbazide or thiosemicarbazone moiety able to undergo an imi-
nothiol/thiourea tautomerization and to generate a thiol  group30,31. It must be noted that the pKa of sulfhydryl 
groups in MBL decreases by about two orders of magnitude, due to the zinc presence, leading to deprotonation 
and strong coordination of the metal  ions32,33. In the active compounds, thiols and thioureas are often associated 
to other electron pair donors that can complement the electron request of the MBL binding  site15,25.
Looking at compound 52 in NDM-1 (Fig. 1a), this active site’s requirement appears properly fulfilled, as also 
confirmed by the good superposition of the central core of the molecule with the H-bond acceptor Molecular 
Interaction Field (MIF; Fig. S2, red contour).
Other compounds found active towards NDM-1 present diverse moieties having electron pairs such as car-
boxylate, sulfhydryl-triazole, benzo-triazole, nitro-triazole, amido-tiazole, sulfhydryl-tiadiazole, sulfone, previ-
ously reported among NDM-1  inhibitors15,34–36.
VIM‑2 inhibition. The VS success rate against VIM-2 was 43%. Overall, ten molecules were confirmed to 
be active against VIM-2 with an inhibitory activity ≥ 50% and, of these, six showed an inhibition higher than 
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70%. Four molecules were originally selected for their potential binding to NDM-1, which belongs to the same 
subclass.
The most potent compound is 31, which demonstrates an inhibition percentage of 97%. Its predicted orienta-
tion in the VIM-2 active site is shown in Fig. S3. Interestingly, the sulfhydryl-triazole moiety of compound 31 is 
present in several of the most active VIM-2 inhibitors, 24, 55 and 59. This class of molecules has been previously 
reported to inhibit several clinically relevant  MBLs35.
Compounds 24 and 54 showed an inhibition ≥ 70% towards both VIM-2 and NDM-1 (Fig. 1b, c, S4, S5). 
While coordinating the zinc ions, compounds 24 and 54 in NDM-1 interact, respectively, with Lys224/211 
and Asn233/220, crucial residues involved in β-lactam recognition and  hydrolysis37. Notably, the conserved 
Asn233/220 forms an oxyanion hole together with Zn1 and is involved in the polarisation of the lactam carbonyl 
upon binding, thus facilitating the nucleophilic attack by the activated hydroxide. Therefore, targeting these resi-
dues might be critical for the design of potent NDM-1  inhibitors15. Interestingly, the mentioned residues appear 
involved in H-bond networks with many other compounds here identified as active towards MBLs.
Other compounds that can inhibit VIM-2 within a 50–70% range include 22, 33, 52 and 61.
KPC‑2 inhibition. A good VS success rate was obtained for KPC-2 with ten compounds validated in vitro 
as active, out of the thirteen selected (77% success rate). On the whole, including those molecules selected for 
the other class A SBL, CTX-M-15, twenty-two molecules showed inhibition between 50 and 70% and five > 70%. 
Table 1.  Library inhibition profile. The inhibitory activity of the compounds was evaluated towards a panel 
of relevant BLs (the percentage of enzyme inhibited fraction is reported except when ≤ 20% and in this case is 
indicated by a hyphen). The same enzyme colour code is used in both Fig. 1 and Chart 1. The colour next to the 
ID code indicates for which BL the compound was originally selected in silico.
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The best performing compound, 9, is shown in Fig. 1d and S6. Compounds bearing triazole, tetrazole and sul-
phonamide moieties were mainly found. With respect to the scaffolds that are preferred by NDM-1 and VIM-2, 
KPC-2 inhibitors miss the sulfhydryl group. Nevertheless, they present electron pair donors that can interact 
with residues Ser70, Lys73, Ser130 and Thr237 in the active site. This common feature may explain the cross 
reactivity of some compounds selected for SBLs, but able to target MBLs as  well38.
CTX‑M‑15 inhibition. The screening performance obtained for CTX-M-15, with only three molecules 
active in vitro, was relatively low, with a 14% success rate. The active compounds, 3, 7 and 11, have quite dif-
ferent structures and a poor inhibition percentage (63% and lower). The best pose, according to the score, the 
number of H-bonds and the superimposition with the Molecular Interaction Fields, is assumed by compound 
7 (Figs. 1e and S7), which forms H-bonds with Ser70 and Ser130 through the indole dione moiety, and with 
Arg274 through the nitro group. Hydrophobic contacts are formed between the indole and Tyr105. Other mol-
ecules among those that were predicted to be active for KPC-2 and NDM-1 also showed some inhibition vs 
CTX-M-15. Overall, thirteen of these molecules, which present a wide range of different chemical structures, 
were detected.
AmpC inhibition. As mentioned, all compounds were also tested vs AmpC, a class C SBL against which only 
last generation inhibitors, such as the recently approved avibactam, are effective. Compounds 40 and 54, which 
were originally selected for VIM-2, were able to exert 50% inhibition on AmpC. The pose of compound 54 is 
shown in Fig. 1f and S8. The complex is stabilised by a number of H-bonds that are formed by the nitro moiety 
with Val121 and Tyr221, by the carbonyl with Asn152 and by the thiosemicarbazide with the catalytic Ser64. As 
mentioned above, pKa predictions, which were performed using  Moka39, and the absence of zinc ions, indicate 
that the most favoured tautomer of the thiosemicarbazide should be the thioureidic form.
Chart 1.  Venn diagram reporting the inhibition profile of active compounds towards the BLs panel. Each 
coloured area refers to a specific BL: CTX-M-15 green, KPC-2 orange, NDM-1 blue, VIM-2 grey, AmpC, pink. 
Compounds showing inhibition ranging 50–70% or > 70% towards, at least, one target are represented by white-
filled and grey-filled circles, respectively, and are located under the curve belonging to that specific enzyme. 
Those exerting a minimum 30% inhibition towards other BLs are located in overlapping areas. The inhibition 
percentage exact values are reported in Table 1.
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Compound 7 chemical structure, not reported in Table 2, is shown in Table S1.
Spectrum of inhibition of the identified MBL inhibitors. All compounds found to be active towards 
VIM-2 are active against NDM-1 as well (Chart 1); in particular compounds 24 and 54 showed the highest inhi-
bition percentage towards both proteins. Interestingly, eight compounds were active only against NDM-1. With 
respect to VIM-2, NDM-1 has a slightly more extensive active  site40, which derives primarily from the orienta-
tion of the two loops L3 (residues 61–67/65–74) and L10 (residues 221–240/205–228), involved in substrate rec-
ognition and hydrolysis in subclass B1 MBLs (Fig. S9). The most important residues on loop L10 are Arg228/185 
and Asn233/190 in VIM-241, Lys224/211 and the same Asn233/210 in NDM-1. Interestingly, Lys224/211 is con-
served in all subclass B1 representatives, apart from the VIM variants. The capability of many of the identified 
candidates to target these residues might enlarge the compound inhibition profile towards different MBLs.
Spectrum of inhibition of the identified SBL inhibitors. A number of compounds has been found 
active towards both class A BLs, CTX-M-15 and KPC-2 (Chart 1). The superposition of the proteins highlights 
the similarity of the active sites: only five residues differ, displaying, indeed, quite conservative substitutions 
(Fig. S10).
Table 2.  Chemical structure of the compounds showing at least 70% inhibition towards one BL.
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X‑ray crystallography of compounds 24 and 31 binary complexes. High-resolution structures of 
compounds 24 and 31 in complex with VIM-2 and NDM-1 MBL have been determined by single-crystal X-ray 
diffraction at 1.60 and 1.38 Å resolution, respectively (Fig. 2, Table S4, S5, Fig. 3a, d). Two molecules per asym-
metric units are present in both experimental models. Indeed, the two protein chains are present as unique ele-
ments in the crystal a.s.u., and the main features of the active site, as well as compound binding orientation, are 
conserved among the complexes.
Figure 1.  Docking pose of some of the most promising compounds in the corresponding BL binding site. (a) 
Compound 52 in NDM-1 (80% inhibition; protein PDB code 5zge). (b, c) Compound 24 in NDM-1 (70%; 5zge) 
and VIM-2 (86%; 2yz3), respectively. (d) Compound 9 in KPC-2 (77%; 3dw0). (e) Compound 7 in CTX-M-15 
(57%; 4hbt). (f) Compound 54 in AmpC (51%; 1kdw). Pictures were prepared with Pymol v1.7.6.4.
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With respect to the apo form of the enzyme the residues defining the active site undergo very minor confor-
mational changes, as well as the two loops, L3 and L10, which define the entrance of the active site. In particular, 
in the case of NDM-1 they experience a slight opening upon binding of the inhibitors, while in VIM-2 their 
position appears quite conserved. The two zinc ions move away from each other a little, to better coordinate the 
ligand electron pair donors. A slight movement in the order of 0.5–0.8 Å is observed with respect to the apo 
structure. Inspection of the difference density and OMIT maps undoubtedly identifies the ligand presence and 
orientation in the modelled state.
In VIM-2 binding site compound 24 orients the central sulfhydryl-triazole-based scaffold deep in the pocket, 
with one of the triazole nitrogen contacting Zn1, while Zn2 is coordinated by the sulfhydryl group. The second 
triazole nitrogen interacts with a crystallographic water molecule. Surprisingly, no other direct contact is formed 
between the inhibitor and the surrounding residues. (Fig. 3a). As mentioned, with respect to the apo form, Zn1 
and Zn2 positions are only marginally shifted, maintaining a distance of about 4.6 Å between them. The side 
chain position of key residues involved in the metal atoms coordination, i.e. His116/94, His118/96, Asp120/98, 
His196/159, Cys221/178 and His263/220, is conserved.
In the binary structures with NDM-1 compound 31 orients similarly to 24, with which it shares the same 
sulfhydryl-triazole moiety. Considering the high structural homology along MBLs and the similar chemical 
structure of inhibitors, a close orientation in the enzyme binding site was expected. With respect to 24 in VIM-
2, compound 31 in NDM-1 is further stabilized by hydrophobic interactions formed with Ile28/35, Val67/73 
and His263/250, and by a hydrogen bond with Gln119/123 (Fig. 3d). The zinc ions maintain the position they 
have in the apo form, as well as the coordinating residues, i.e. His116/120, His118/122, Asp120/124, His196/189, 
Cys221/208, His263/250.
X‑ray crystallography vs modelling binding prediction. Disappointingly, the crystallographic poses 
of the ligands are quite different from that predicted as the most promising by molecular docking simulations. 
For compound 24 in VIM-2, the docking prediction orients the molecule in the opposite way, where both zinc 
ions are coordinated by the sulfhydryl group and stabilized by additional hydrogen bonds with Arg228/185 
(Figs. 1c, 3b). Poses more similar to those identified by X-ray analyses were also produced by docking simula-
tions (Fig. 3c) but were not ranked as the best ones. The superposition of the X-ray and of the most similar 
docking pose for compound 24 is reported in Fig. 3c. Still, a slight adjustment in the pose orientation can be 
observed, in particular because of the presence of Phe61/62, not detected in the X-ray binary complex. The lack 
of the residue side-chain is likely associated to a higher flexibility and opening of the loop L3 observed in the here 
reported structure, with respect to the structure used for docking simulations.
For compound 31, the pose selected during the virtual screening was actually the one most similar to the 
crystallographic pose (Fig. 3f and S3) but was not the one that received the highest score in silico (Fig. 3e). It 
should be noted that the amide sidechain of Gln119/123 is flipped in the X-ray binary complex compared to the 
structure used for docking simulations, allowing it to interact with the ligand pyridyl nitrogen. We can observe 
a slight shift towards His196/189, possibly because of the flipped Gln119/123 or, alternatively, for the absence of 
water molecules in docking simulations. As shown, in fact, both compounds are stabilized by a water interacting 
with one of the triazole nitrogen atoms (Fig. 3a,d). The highest ranking was, instead, assigned to a conformation 
of compound 31 having the opposite orientation with respect to the crystallographic one (Fig. 3e).
Figure 2.  Binary complexes of compound 24 binding to VIM-2 and of compound 31 binding to NDM-1. 
(a) Omit map of 24:VIM-2 binary complex shown at 3.5 σ contour level. (b) 31: NDM-1 binary complex. The 
ligand and the residues lining the pocket are shown as capped sticks, the Zn ions as grey spheres.
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Figure 3.  (a) Binary complex of compound 24 binding to VIM-2. (b) Superposition of the crystallographic 
(magenta) and of the originally selected docking pose (yellow) of compound 24 in VIM-2 binding site. (c) 
Superposition of the crystallographic (magenta) and of the most similar docking pose (yellow) of compound 
24 in VIM-2 binding site. The protein of the binary X-ray complex is coloured grey, while the structure used for 
docking simulation is violet (d). Binary complexes of compound 31 binding to NDM-1. (e). Superposition of 
the crystallographic (green) and of the best ranked docking pose (orange) of compound 31 in NDM-1 binding 
site. The protein of the binary X-ray complex is coloured grey, while the structure used for docking simulation is 
cyan (f). Superposition of the crystallographic (green) and of the originally selected, and most similar docking 
pose (orange), of compound 31 in NDM-1 binding site. Red spheres correspond to water molecules.
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Thus, even if molecular docking guided the selection of the most promising candidates and, indeed, allowed 
the identification of molecules active towards the selected targets, the predicted orientation, in particular for 
compound 24, and the zinc coordination, turned out to be misleading. This failure is likely due to several factors: 
the flexibility of part of the site that is not taken into account, the lack of waters in docking, and an overestima-
tion of the sulphydryl group capability to coordinate the two zinc ions, with respect to the triazole nitrogens. 
These findings represent valuable indications to guide any further docking simulation of similar compounds in 
metallo-based proteins in general and in MBLs binding site in  particular42,43.
Identification and characterization of compounds inhibiting BLs of different molecular 
classes. Most interestingly, some of the compounds were cross-class BLIs, being able to target BLs belonging 
to different classes (Chart 1). The largest inhibition spectrum was observed for compounds 40 and 46, located 
at the centre of the Venn chart. Compound 46, in particular, inhibits CTX-M-15 at 55%, KPC-2 at 66%, AmpC 
at 32%, NDM-1 at 79% and VIM-2 at 45%. Compound 40 shows good inhibition towards KPC-2, NDM-1 and 
AmpC as well (41%, 71% and 50%, respectively). Compound 59 also presents interesting results for CTX-M-
15 and KPC-2 (49% and 46%, respectively), and a good inhibition against NDM-1 and VIM-2 (62% and 81%, 
respectively). The superpositions of the two MBLs and of the three SBLs with compound 59 docked in the 
binding site are reported in Figs. S11 and S12. The orientation of the compound is well conserved in NDM-1 
and VIM-2, reflecting the similarity of the two binding sites. Furthermore, the poses in KPC-2 and CTX-M-15 
are also similar, with the exception of the furan ring, which appears to be twisted. A quite different orientation 
can be observed in AmpC. Interesting compounds are also 24 and 52, which provided good inhibition against 
NDM-1 and VIM-2. In particular, compound 24 inhibits NDM-1 at 70% and VIM-2 at 86%, while compound 
52 at 80% and 62%, respectively.
For some of the most interesting compounds, those being predicted broad-spectrum or strong MBLs inhibi-
tors, the inhibition constant towards relevant BLs was measured (Table 3). Interestingly, all tested molecules 
showed inhibition towards MBL enzymes, with Ki values ranging from 60 to 10 μM. Compound 52 demon-
strated to be the most active towards NDM-1. Compound 40 also showed, although to a lesser extent, inhibi-
tion of CTX-M-15 ESBL enzyme, which ultimately confirms the cross-class inhibition potential of some of the 
inhibitors described herein and the validity of the in silico screening approach used in this study. Indeed, many 
identified compounds ultimately proved to be ligands of the predicted targets, either by X-ray crystallography 
or enzyme assays.
Evaluation of the synergistic activity of the selected compounds. The capability of compound 
40, selected on the basis of its broad-spectrum activity, to potentiate the activity of a β-lactam antibiotic was 
investigated using recombinant isogenic E. coli strains producing the various BLs of the enzyme screen panel, 
including ESBL CTX-M-15, carbapenemase KPC-2, subclass B1 MBLs VIM2 and NDM-1 and P. aeruginosa 
AmpC (class C) (Table 4). The compound did not, expectedly, show any direct antibacterial activity, but was able 
to potentiate the activity of ampicillin, depending on the produced β-lactamase type. The susceptibility of the 
Table 3.  Inhibition constants of compounds 24, 40 and 52 measured on some representative class A (serine-) 
and class B (metallo-) β-lactamases. Ki values were determined using the reporter substrate method and a 
competitive model of inhibition.
Compound β-lactamase Ki (µM)
24 VIM-2 41 ± 4
40
CTX-M-15 150 ± 12
NDM-1 58 ± 9
52 NDM-1 10.7 ± 1.4
Table 4.  In vitro antibacterial synergistic activity of compound 40 on recombinant isogenic E. coli strains 
evaluated by the disk diffusion method (See Materials and Methods for details). DH5α strain was transformed 
with a derivative of the pLB-II vector, in which the β-lactamase gene was cloned)44. Avibactam and EDTA were 
used as inhibition controls for SBLs and MBLs, respectively. – not determined.
Plasmid carried by the E. coli 
DH5α strain
Diameter of growth inhibition zone (mm)
Ampicillin (10 µg) Ampicillin (10 µg) + 40 (80 µg)
Ampicillin (10 µg) + avibactam 
(4 µg)
Ampicillin (10 µg) + EDTA 
(70 µg) 40 (80 µg)
pLBII-CTX-M-15  ≤ 6 16 26 –  ≤ 6
pLBII-KPC-2 9 11 22 –  ≤ 6
pLBII-AmpCP. aeruginosa 19 19 25 –  ≤ 6
pLBII-VIM-2 9 17 – 24  ≤ 6
pLBII-NDM-1 16 18 – 21  ≤ 6
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strains producing CTX-M-15 or VIM-2 was significantly increased in the presence of 40, while a more modest 
effect was observed with strains producing KPC-2 or NDM-1. No effect was observed on the strain producing an 
AmpC-type enzyme (PDC-1). It should be noted that the contribution of these different enzymes to ampicillin 
resistance also largely varies.
Based on these encouraging results, the synergistic activity of 40 and other compounds was tested on clinical 
isolates producing different types of β-lactamases, including a plasmid-encoded class C enzyme CMY-2, KPC-3 
serine-carbapenemase, VIM-1 and NDM-1 metallo-carbapenemase (Table 5). Interestingly, compound 40 was 
able to reduce the MIC of imipenem from 16 to 1 μg/mL in an NDM-1 producing clinical isolate, being below 
the resistance breakpoint as defined by both CLSI and EUCAST. The potentiation effect of this compound was 
lower in other strains. For the other tested compounds, and in apparent contrast with their inhibition profile, 
no significant MIC reduction was observed, indicating that such compounds do not likely have the potential 
to reach the periplasmic space. However, it is not clear at this stage whether this would rely on the compound 
specific physical–chemical properties or whether the compounds could be substrate of efflux pumps, commonly 
produced by MDR clinical isolates.
conclusions
Herein, we have presented the parallel screening that led to a library of 66 validated candidates targeting BLs: class 
A and C SBLs (CTX-M-15, KPC-2, AmpC) and class B1 MBLs (NDM-1 and VIM-2). Overall, the VS campaign, 
performed with the ad hoc developed version of the molecular docking software FLAPdock, gave quite good 
results, with a high percentage of active molecules being found: ten compounds for CTX-M-15, twenty-two for 
KPC-2, thirty-one for NDM-1 and ten for VIM-2. Moreover, two compounds were found active against AmpC.
Specific scaffolds were identified as being promising for each class. For class B1 NDM-1, the active compounds 
often present a thiol, a thiosemicarbazide or thiosemicarbazone moiety or, in general, electron pair donors. 
For VIM-2, presenting more stringent structural requirements, triazole-based ligands appeared to be the most 
efficient. Despite the slightly different binding site architectures, several compounds were found to be able to 
concomitantly inhibit both enzymes. Interestingly, the most active molecules present a triazole-thiol moiety.
Good results were also found for SBLs and, in particular, for class A KPC-2. This enzyme, just like NDM-1 
and VIM-2, requires the presence of compounds having electron pairs that can interact with the catalytic serine 
and with the other H-bond donor residues lining the pocket. The highest inhibition percentage was found for 
sulfonamide and tetrazole-based derivatives. Fewer promising results were obtained for class A CTX-M-15 and 
class C AmpC and no specific scaffold was identified. Two X-ray crystallographic complexes were solved at high 
resolution with NDM-1 and VIM-2, deciphering the binding requirements for MBLs inhibition, and providing 
valuable insights to be considered in molecular docking simulations when metallo-proteins are involved.
Interestingly, many compounds were found to inhibit BLs belonging to same class and a few to inhibit BLs 
belonging to different classes. More in detail, three compounds (40, 46 and 59) target all considered BLs, result-
ing broad-spectrum inhibitors. Furthermore, compound 40 inhibited both CTX-M-15 and NDM-1 BLs with Ki 
values of ≈100 μM and showed a significant 16-fold potentiation of imipenem activity on a NDM-1-producing E. 
coli clinical isolate, with a resulting MIC value in the susceptibility range. Although this was achieved at a rather 
high concentration of inhibitor (32 μg/mL), these data allowed to identify 40 as a promising starting point for 
the design of completely novel BL inhibitors, with demonstrated in vitro activity in whole cell assays.
Inhibitors sharing similar chemical structures and with comparable inhibition activity have been already 
reported by  ourselves34,35,45, and by other  groups46,47. However, with respect to the here presented compounds, the 
molecules so far proposed in literature were designed to act only towards MBLs. To our knowledge, this is one of 
Table 5.  In vitro antibacterial activity of imipenem (IPM), ceftazidime (CAZ) and cefepime (FEP), in the 

























IPM IPM IPM CAZ FEP
None 16 8 16 128 2
10 16 8 16 128 2
20 16 8 16 128 2
24 16 8 16 128 2
31 16 8 16 128 2
32 16 8 16 128 2
40 16 4 1 128 1
46 16 8 16 128 2
52 16 8 8 128 1
55 16 8 16 128 2
59 16 8 16 128 1
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the first computational studies that succeeded in the identification of broad-spectrum inhibitors active towards 
BLs belonging to different classes. The difficulty of designing and developing non-covalent inhibitors that can 
target SBLs, the worrisome spread of MBLs and, most importantly, the co-production of carbapenemases belong-
ing to different classes, highlight the significance of the obtained results. The development of ligands acting as 
broad-spectrum inhibitors would represent a significant step forward for the containment of antibiotic resistance.
With respect to recently approved molecules with broad spectrum profile and nanomolar  affinity12, the here 
identified inhibitors, despite their low micromolar activity, share a cross-class inhibition and represent novel 
drug-like leads with valuable biological activity to be directed to hit-to-lead development.
Materials and methods
Molecular modelling. MBL numbering. For clarity, when referring to MBL residues, both the consensus 
and the PDB numbering will be given in the text (consensus/PDB)48. In the figures, only the consensus number-
ing scheme has been adopted. For class C AmpC we adopted the SANC (Standard Alignment-based Number-
ing) standard numbering  scheme49.
Protein modelling. Protein X-ray structures were retrieved from the Protein Data Bank, and chosen according 
to the crystallographic resolution, the absence of mutations and the presence/absence of complexed ligands, in 
order to better evaluate the intrinsic dynamics of the protein matrix and local binding site flexibility. When rel-
evant ligand-induced binding-site rearrangement (induced-fit effect) was observed, more than one X-ray struc-
ture was used for the same protein. Co-crystallized ligands, along with water molecules, were removed. Each 
structure was carefully inspected using the flapsite algorithm (implemented in FLAP, developed and licensed 
by Molecular Discovery Ltd.) to automatically detect the binding site pocket where the compounds would be 
docked.
CTX-M-15 was considered in both the apo and holo form in complex with avibactam (PDB codes 4hbu and 
4hbt, respectively), KPC-2 in the apo form (PDB code 3dw0), NDM-1 in the apo and holo form in complex with 
ampicillin (PDB codes 3spu and 5zge, respectively), VIM-2 in complex with a mercaptocarboxylate inhibitor 
(PDB codes 2yz3). Finally, the complex with 4-carboxyphenilboronic acid was used for AmpC (PDB code 1kdw).
Database treatment. The Specs database (www.specs .net) was screened against the selected β-lactamases. The 
original library of about 300,000 compounds was filtered according to molecule logP, as predicted by  MoKa39. 
Only compounds with logP values lower than 3 (thus likely to be soluble for the subsequent in vitro analyses) 
were retained. Tautomers and protomers were built using MoKa. Only tautomers and protomers with a pre-
dicted percentage higher than 10 were retained. The final library contained about 27,000 compounds.
Virtual screening. Structure-based virtual screening (SBVS) analyses were performed using FLAPdock imple-
mented in FLAP (Fingerprint for Ligands and Proteins), developed and licensed by Molecular Discovery  Ltd50. 
FLAP is based on GRID Molecular Interaction Fields (MIFs), which describe both ligands and protein active 
sites, and can be used to find complementary ligands with a receptor-based pharmacophore  approach38,51.
The FLAPdock fragment‑based approach. FLAPdock, recently published and described  in38, is a fragment-
based docking approach. Ligands are split into fragments and each fragment is first scored using a weighted sum 
of the similarity between the GRID MIFs (shape, H-bond donor, H-bond acceptor, hydrophobicity) that are 
calculated for the active site and the pseudo-MIFs calculated for the fragment. A more accurate scoring function 
(FLAP S-Score), which includes both Lennard–Jones and dielectric corrected Coulombic energetic terms, is 
then applied. The best ranked solutions are retained and the fragment anchor point used to incrementally con-
struct the ligand, while various torsion angles for each added fragment are explored at each stage, retaining the 
best ranked solutions for the next fragment addition. For sites containing metals, any known metal-interacting 
groups in the ligand are biased towards interacting with the metal ion via their charge interaction and, in the 
specific case of MBLs, sulfhydryl compounds are considered deprotonated because of the zinc effect, which low-
ers the pKa of bound thiol groups by about two orders of  magnitude32,33.
The library was first docked in each of the selected BL binding site with lower accuracy in order to speed up 
the calculations. The best 1% ranked molecules of the library were then re-docked using the higher accuracy 
modality, which takes more computational time, but provides more accurate predictions.
Compound selection. The compounds docked within the protein binding site were visually inspected. The most 
interesting molecules, according to the FLAP S-Score, the number of hydrogen bonds formed with the pocket 
surrounding residues and the chemical diversity, were purchased and tested in inhibition assays. In some cases, 
the mentioned criteria indicated that a compound was promising for more than one target. This happened more 
often for NDM-1 and VIM-2, which belong to the same class and share a relatively high similarity at the binding 
site level (see the Results section for further details). These compounds have a higher chance of being broad-
spectrum and were prioritized during selection.
The 66 selected molecules were purchased and experimentally tested for inhibition towards CTX-M-15, 
KPC-2, AmpC, NDM-1 and VIM-2 (Tables S1–S3).
Protein production, purification and inhibition assays. All proteins employed in the in vitro vali-
dation were produced and purified as already  reported38. For proteins used in the crystallographic studies the 
following protocols were employed.
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Cloning, production and purification of recombinant VIM‑2. BlaVIM-2 gene lacking signal peptide (26–266, 
UniProtKB—Q9K2N0) was purchased by Eurofins Genomics, and directly cloned into pETite N-His SUMO 
Kan Vector (Lucigen). Overexpression of the N-His SUMO VIM-2 protein was performed transforming E. coli 
Lemo21(DE3) cells (NEB) and grown in LB medium (25 mg/L kanamycin, 17 mg/L chloramphenicol) at 37 °C. 
Large scale expression was induced at 0.5 OD600 with 0.2 mM Isopropyl-β-d-1thiogalactopyranoside (IPTG), 
overnight at 25 °C. Cell pellet was resuspended in lysis buffer (20 mM Tris–HCl pH 8.0, 150 mM NaCl, 1 mM 
ZnCl2, 10% glycerol and 20 mM imidazole) supplemented with protease inhibitors cocktail (Roche), and lysed 
by French press. N-His SUMO VIM-2 was purified from soluble fractions through IMAC (HisTrap HP 1 mL 
column, GE Healthcare) and eluted by 0.5 M imidazole. Fractions containing N-His SUMO VIM-2 were buffer 
exchanged with PD10 desalting columns (GE Healthcare) in 20 mM Tris–HCl pH 7.5, 150 mM NaCl and 10% 
glycerol. N-His SUMO removal was performed through cleavage of the purified protein using SUMO express 
Protease (Lucigen). SUMO express protease and uncleaved N-His SUMO VIM-2 were removed by IMAC.
Cloning Expression and purification of recombinant NDM‑1. NDM-1 protein without signal peptide (28–270, 
UniProtKB—C7C422) was produced and purified as described  before52.
All the enzymes used in this study were further purified by size exclusion chromatography (Superdex 200 
Hiload 16/60, GE Healthcare) and stored at 193 K for crystallization purposes. Optimized buffers were used for 
each of them: 20 mM Hepes, 100 mM NaCl pH 7.0 for NDM-1; 30 mM Hepes, 150 mM NaCl pH 7.1 for VIM-2.
Enzyme inhibition assays. The entire library of 66 purchased compounds was screened, without further puri-
fication, against the selected β-lactamase panel using a colorimetric assay and a 96-well multiplate reader (Spec‑
tramax‑190-Molecular Devices). Each compound was dissolved in DMSO in 10 mM stock solutions. Inhibi-
tion activity assays were performed in the reaction buffer, which consisted of 50 mM PB + 50 mM KCl, at pH 
7.0 and 25 °C with 0.01% v/v Triton x-100, to avoid compound aggregation and promiscuous inhibition, and 
using CENTA 250 µM as the reporter  substrate53,54. Reactions started with the addition of the enzyme and were 
monitored at 405 nm, over a time course of 300 s. Inhibition activity was tested at a fixed ligand concentration 
of 200 µM, and three replicates were performed for each compound. Standard error was below 10%. Inhibition 
constants were determined using a competitive inhibition model and by measuring the initial reaction rate of 
hydrolysis of a reporter substrate (150 μM imipenem, for VIM-2 and NDM-1 enzymes, or 100 μM cephalothin 
for CTX-M-15) in 50 mM HEPES buffer (pH 7.5), by means of spectrophotometric assays in the absence and 
presence of a variable inhibitor concentration, as previously  described55. Reaction rates were measured in trip-
licates.
X‑ray crystallography. Purified truncated NDM-1 β-lactamase was crystallized according to previously 
determined  conditions52, while VIM-2 was submitted to crystallization trials according to well established proto-
cols proved to be successful with other  ligands56. Briefly, for NDM-1, a purified protein sample was concentrated 
to 50 mg/mL and submitted to an isothermal vapor diffusion crystallization setup (0.8 μl total volume drops, 1:1 
protein-precipitant ratio, 293 K). NDM-1 in complex with compounds 31 was obtained only in a two-phase co-
crystallization setup, according to the procedure recently proposed by Leiros and  colleagues56, while all the other 
conditions and compounds tested failed to give crystals of NDM-1 in complex with any compounds. The same 
two-phase strategy proved to be successful for both NDM-1 and VIM-2. VIM-2, concentrated to 10 mg/mL, 
was crystallized as previously  described56,57. Briefly, VIM-2 supplemented with 0.5 mM  ZnCl2 was crystallized 
in isothermal vapor diffusion conditions (0.8 μL total volume drops, 1:1 protein-precipitant ratio, 293 K), using 
as precipitant buffer 0.25 M magnesium formate, 27% PEG3350. Diffracting crystals of VIM-2 in complex with 
24 were obtained with hand-made fresh crystallization trials on top of dried 24 compound, as indicated above.
In all cases, crystals were cryo-protected with 20% ethylene glycol v/v added to the precipitant solution and 
flash frozen in liquid nitrogen. Diffraction data were collected at the Swiss Light Source (SLS) at the Paul Scher-
rer Institut in Villigen, Switzerland. Both NDM-1 and VIM-2 crystals gave complete datasets and diffracted to 
resolutions better than 1.5 Å.
The structures were solved through molecular replacement by Phaser  software58, using ccp4i2  interface59. The 
protein models 6Q2Y for NDM-1 and 4BZ3 for VIM-2 were used as starting  template57. Refinement was carried 
out by  Refmac560, refine (Phenix interface)61 and manual adjustment through the graphic software  Coot62. The 
identification of compounds bound to the MBLs active sites was performed through a detailed inspection of 
Fourier Difference maps. Ligand molecules were built and optimized by Elbow (Phenix)63, and then fitted in the 
maps using Coot tools. Their position was adjusted by local refinement and further steps of global refinement. 
Completion of the models was achieved by water molecules fitting and other ligands identification, as metal 
ions and buffer molecules. In particular, the analysis of both NDM-1 and VIM-2 crystals anomalous scattering 
maps confirmed the presence of the two conserved and catalytically relevant zinc ions in the active sites (data 
not shown). Likewise, for NDM-1 crystals we identified calcium ions coordinated by acidic residues nearby the 
catalytic site, as already  described52, while for VIM-2 we detected additional zinc ions coordinated by formate 
molecules at the interface, with symmetry mates in the crystal packing. PyMOL Molecular Graphics software 
and Phenix tool for omit maps calculations were used to generate illustrations.
In vitro antibacterial susceptibility assays. The potential of the described molecules to increase the 
activity of a β-lactam antibiotic was investigated using recombinant isogenic E. coli strains producing different 
types of β-lactamases, including the class A ESBL CTX-M-15 and the KPC-2 carbapenemase, the subclass B1 
MBLs VIM-2 and NDM-1 and the class C P. aeruginosa AmpC (PDC-1) enzyme. The β-lactamase genes were 
cloned in the pLB-II vector as previously  described44, and the resulting plasmid used to transform E. coli DH5α. 
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A disk diffusion method (known as combo test) was used (considering its lower requirements in terms of com-
pound quantity) to evaluate the synergistic activity of the compounds, as previously  described27. Briefly, the 
diameter of the growth inhibition zone of an ampicillin-containing disk (10 µg, Oxoid, Milan, Italy), on which 
either the tested compounds (80 µg), EDTA (MBL inhibition control, 70 µg) or avibactam (SBL inhibition con-
trol, 4 µg) were dispensed (max. volume, 15 μl), were compared to that obtained with the antibiotic disk control. 
Results were read after aerobic incubation at 35 ± 1 °C for 18–24 h.
Alternatively, the broth microdilution method was used. In this case, clinical isolates producing a plasmid-
encoded class C enzyme CMY-2, a KPC-3 serine-carbapenemase, VIM-1 or NDM-1 metallo-carbapenemase were 
 used64. Strains were in our antibiotic-resistant clinical isolates collection and were recovered from various Italian 
hospitals. Minimal Inhibitory Concentrations (MICs) of imipenem, ceftazidime and cefepime were determined 
at least twice by the broth microdilution method in Mueller–Hinton broth, according to the Clinical Laboratory 
Standards Institute  guidelines65, in the absence and presence of 32 μg/mL of the tested compound. Plates were 
incubated aerobically at 35 ± 1 °C for 18–24 h before reading.
Data availability
Atomic coordinates and structures factors have been deposited in The Protein Data Bank for immediate release 
as PDB ID: 6tgi (VIM-2 in complex with compound 24) and 6tgd (NDM-1 in complex with compound 31).
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